1. Home
  2. ZLAB vs KRYS Comparison

ZLAB vs KRYS Comparison

Compare ZLAB & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • KRYS
  • Stock Information
  • Founded
  • ZLAB 2013
  • KRYS 2015
  • Country
  • ZLAB China
  • KRYS United States
  • Employees
  • ZLAB N/A
  • KRYS N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ZLAB Health Care
  • KRYS Health Care
  • Exchange
  • ZLAB Nasdaq
  • KRYS Nasdaq
  • Market Cap
  • ZLAB 4.3B
  • KRYS 4.3B
  • IPO Year
  • ZLAB 2017
  • KRYS 2017
  • Fundamental
  • Price
  • ZLAB $34.96
  • KRYS $138.66
  • Analyst Decision
  • ZLAB Buy
  • KRYS Strong Buy
  • Analyst Count
  • ZLAB 5
  • KRYS 11
  • Target Price
  • ZLAB $54.28
  • KRYS $205.27
  • AVG Volume (30 Days)
  • ZLAB 860.8K
  • KRYS 415.0K
  • Earning Date
  • ZLAB 08-07-2025
  • KRYS 08-04-2025
  • Dividend Yield
  • ZLAB N/A
  • KRYS N/A
  • EPS Growth
  • ZLAB N/A
  • KRYS 36.22
  • EPS
  • ZLAB N/A
  • KRYS 4.91
  • Revenue
  • ZLAB $427,799,000.00
  • KRYS $359,205,000.00
  • Revenue This Year
  • ZLAB $45.16
  • KRYS $40.10
  • Revenue Next Year
  • ZLAB $56.81
  • KRYS $49.73
  • P/E Ratio
  • ZLAB N/A
  • KRYS $28.21
  • Revenue Growth
  • ZLAB 32.56
  • KRYS 116.08
  • 52 Week Low
  • ZLAB $16.01
  • KRYS $122.80
  • 52 Week High
  • ZLAB $44.34
  • KRYS $207.84
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 45.24
  • KRYS 42.81
  • Support Level
  • ZLAB $33.17
  • KRYS $132.31
  • Resistance Level
  • ZLAB $39.64
  • KRYS $138.18
  • Average True Range (ATR)
  • ZLAB 1.19
  • KRYS 6.26
  • MACD
  • ZLAB -0.31
  • KRYS -2.12
  • Stochastic Oscillator
  • ZLAB 22.29
  • KRYS 28.63

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Share on Social Networks: